Pemafibrate is used in the treatment of Hyperlipidaemia and Dyslipidaemias. Pemafibrate was developed by Originator Kowa Pharmaceutical and Developer Jaeb Center For Health Research.
The API has now reached off-patent status, after being launched in 2017.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Pemafibrate and many others, contact info@pharmacheminvestor.com